Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis.
10.1097/CM9.0000000000001817
- Author:
Ran PAN
1
;
Xiaolun WANG
1
;
Min SHU
1
;
Jaydeep DAS
2
;
Manik KALRA
2
;
Zhidong WANG
1
Author Information
1. Beijing Novartis Pharma Co. Ltd., Shanghai, China.
2. Novartis Healthcare Pvt. Ltd., Hyderabad, India.
- Publication Type:Systematic Review
- MeSH:
Adalimumab/therapeutic use*;
Adolescent;
Adult;
Antibodies, Monoclonal, Humanized;
Humans;
Infliximab/therapeutic use*;
Psoriasis/drug therapy*;
Severity of Illness Index;
Treatment Outcome
- From:
Chinese Medical Journal
2021;135(1):11-19
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Psoriasis is a common, chronic, immune-mediated inflammatory skin disease with increased epidermal proliferation. The objective of this review was to systematically identify the evidence and perform a network meta-analysis (NMA) to estimate the relative efficacy of secukinumab (SEC) against adalimumab (ADA) and infliximab (INF) for the treatment of moderate-to-severe plaque psoriasis.
METHODS:A systematic literature review (SLR) was conducted according to a pre-specified protocol to identify relevant studies. Initially, the databases were searched from database inception till June 2013, and the SLR was updated in April 2020. The eligibility criteria included adult patients (≥18 years old) with moderate-to-severe plaque psoriasis, and the SLR included randomized controlled trials (RCTs). The comparators of interest were SEC, ADA, INF, and placebo (PLA), while outcomes of interest were Psoriasis Area and Severity Index (PASI) (50, 75, and 90) at weeks 12, 16, and 24. A Bayesian NMA for PASI was utilized with a framework that evaluated the probability of PASI responses in different categories of PASI thresholds within a single model.
RESULTS:A total of 23 RCTs that assessed the efficacy of SEC, ADA, and INF in patients with moderate-to-severe plaque psoriasis were identified. At 12 weeks, SEC was associated with a significantly better response compared with PLA and ADA for PASI 75 and 90, while response results were comparable against INF. At 12 weeks, risk ratio (95% confidence interval) derived from NMA for SEC vs. ADA and INF for PASI 75 was 1.35 (1.19, 1.57) and 1.01 (0.90, 1.18), respectively. At the 16-week and 24-week time interval, SEC was significantly better than PLA, ADA, and INF for PASI 75 and 90.
CONCLUSION:Efficacy of SEC in the treatment of patient populations with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
